Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022

Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023

Published:2023-02-17 Issue:7 Volume:72 Page:177-182
ISSN:0149-2195
Container-title:MMWR. Morbidity and Mortality Weekly Report
language:
Short-container-title:MMWR Morb. Mortal. Wkly. Rep.

Author:

Fleming-Dutra Katherine E.,Ciesla Allison Avrich,Roper Lauren E.,Smith Zachary R.,Miller Joseph D.,Accorsi Emma K.,Verani Jennifer R.,Shang Nong,Derado Gordana,Wiegand Ryan E.,Pilishvili Tamara,Britton Amadea,Link-Gelles Ruth

Publisher

Centers for Disease Control MMWR Office

Subject

Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology

Reference10 articles.

1. Interim recommendations of the Advisory Committee on Immunization Practices for use of Moderna and Pfizer-BioNTech COVID-19 vaccines in children aged 6 months–5 years—United States, June 2022.;Fleming-Dutra;MMWR Morb Mortal Wkly Rep,2022

2. Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age.;Anderson;N Engl J Med,2022

3. Food and Drug Administration; Vaccines and Related Biological Products Advisory Committee. FDA briefing document: EUA amendment request for Pfizer-BioNTech COVID-19 vaccine for use in children 6 months through 4 years of age. Presented at the Vaccines and Related Biological Products Advisory Committee meeting, Silver Spring, MD; June 15, 2022. https://www.fda.gov/media/159195/download

4. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants.;Accorsi;JAMA,2022

5. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance.;Fleming-Dutra;JAMA,2022

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk benefit analysis to evaluate risk of thromboembolic events after mRNA COVID-19 vaccination and COVID-19;npj Vaccines;2024-09-13

2. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial;The Lancet Infectious Diseases;2024-07

3. Risk of Blood Clots After COVID-19 Vaccination and Infection: A Risk-Benefit Analysis;2024-06-07

4. Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children <5 Years of Age;Pediatrics;2024-05-17

5. Effectiveness of mRNA BNT162b2 and inactivated CoronaVac vaccines against severe COVID-19 outcomes among non-hospitalised children aged 1-3 years with SARS-CoV-2 Omicron infection;International Journal of Antimicrobial Agents;2024-03